Idarubicin extravasation

Idarubicin—monitor cumulative dose for possible cardiac toxicity vesicant—avoid extravasation... 

Idarubicin -anthracycline antitumor antibiotic DNA intercalating agent -bone marrow suppression -nausea and vomiting—mild to moderate -mucocutaneous effects (mucositis, stomatitis, diarrhea) -vesicant if extravasated -cardiotoxicity (150 mg/M2) -elevated liver function tests... 

Idarubicin Nausea and vomicing cissue damage on extravasation Bone marrow depression alopecia stomatitis myocardial toxicity diarrhoea... 

The recommended dosage for idarubicin (Idamycin) is 12 mg/m daily for 3 days by intravenous injection in combination with cytarabine. Slow injection with care over 10 to 15 minutes is recommended to avoid extravasation, as with other anthracyclines. 

Daunorubicin, doxorubicin, epirubicin, and idarubicin usually are administered intravenously. Careful infusion over 10-15 minutes is recommended to prevent extravasation, since severe local vesicant action may result. The drugs are cleared by a complex pattern of hepatic metabolism and biliary excretion. The plasma disappearance curve for doxorubicin is multipha-sic, with elimination half-lives of 3 hours and - SO hours. All anthracyclines are converted to an active alcohol intermediate that plays a variable role in their therapeutic activity. Idarubicin has a tj of 15 hours, and its active metabolite, idarubicinol, has a tj of - 40 hours. There is rapid upt e of the drugs in the heart, kidneys, lungs, liver, and spleen. They do not cross the blood-brain barrier. Daunorubicin and doxorubicin are eliminated by metabolic conversion to a variety of aglycones and other inactive products. Idarubicin is primarily metabolized to idarubicinol, which accumulates in plasma and likely contributes significantly to its activity. Clearance is delayed in the presence of hepatic dysfunction, and at least a 50% initial reduction in dose should be considered in patients with elevated serum bilirubin levels. 

---